Observations that make me uncomfortable, page-6

Yeah I was stumped at that comment too. If Phase 2 results are anything to go on then there was impressive reduced risk of progression which was clearly more than a marginal statistical significance and which warrnated a costly Ph3 trial. i guess it all depends on the Ph3 results but it the desired positive results are obtained then I cant see ACL struggling to license its technology, or to have potential proof of platform concept for a whole host of standard of care drugs.